EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access

Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)

Jeffrey S Weber iD, Dirk Schadendorf iD, Michele Del Vecchio, James Larkin iD, Victoria Atkinson, Michael Schenker iD, Jacopo Pigozzo iD, Helen Gogas iD, Stéphane Dalle, Nicolas Meyer, Paolo A Ascierto iD, Shahneen Sandhu iD und 24 weitere

Journal of Clinical Oncology · 20.01.2023 · 41 (3) · 517-527

DOI: 10.1200/jco.22.00533 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.01.2023. Verfasst von Jeffrey S Weber und 35 weiteren Autor:innen. Beteiligte Einrichtung: Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY. Hauptthemen laut MEDLINE: Ipilimumab, Melanoma, Nivolumab, Skin Neoplasms. Die Arbeit wurde bisher 169-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Ipilimumab and nivolumab have each shown treatment benefit for high-risk resected melanoma. The phase III CheckMate 915 trial evaluated adjuvant nivolumab plus ipilimumab versus nivolumab alone in patients with resected stage IIIB-D or IV melanoma. PATIENTS AND METHODS In this randomized, double-blind, phase III trial, 1,833 patients received nivolumab 240 mg once every 2 weeks plus ipilimumab 1 mg/kg once every 6 weeks (916 patients) or nivolumab 480 mg once every 4 weeks (917 patients) for ≤ 1 year. After random assignment, patients were stratified by tumor programmed death ligand 1 (PD-L1) expression and stage. Dual primary end points were recurrence-free survival (RFS) in randomly assigned patients and in the tumor PD-L1 expression-level < 1% subgroup. RESULTS At a minimum follow-up of approximately 23.7 months, there was no significant difference between treatment groups for RFS in the all-randomly assigned patient population (hazard ratio, 0.92; 95% CI, 0.77 to 1.09; P = .269) or in patients with PD-L1 expression < 1% (hazard ratio, 0.91; 95% CI, 0.73 to 1.14). In all patients, 24-month RFS rates were 64.6% (combination) and 63.2% (nivolumab). Treatment-related grade 3 or 4 adverse events were reported in 32.6% of patients in the combination group and 12.8% in the nivolumab group. Treatment-related deaths were reported in 0.4% of patients in the combination group and in no nivolumab-treated patients. CONCLUSION Nivolumab 240 mg once every 2 weeks plus ipilimumab 1 mg/kg once every 6 weeks did not improve RFS versus nivolumab 480 mg once every 4 weeks in patients with stage IIIB-D or stage IV melanoma. Nivolumab showed efficacy consistent with previous adjuvant studies in a population resembling current practice using American Joint Committee on Cancer eighth edition, reaffirming nivolumab as a standard of care for melanoma adjuvant treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IpilimumabMelanomaNivolumabSkin NeoplasmsHumansAdjuvants, ImmunologicAntineoplastic Combined Chemotherapy ProtocolsB7-H1 AntigenDouble-Blind MethodNeoplasm Staging

Substanzen

Adjuvants, ImmunologicB7-H1 AntigenIpilimumabNivolumab

Autor:innen und Institutionen

  • Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY.
  • Department of Dermatology, University of Essen and the German Cancer Consortium, Partner Site, Essen, Germany.
  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • The Royal Marsden NHS Foundation Trust, London, United Kingdom.
  • Division of Cancer Services, Gallipoli Medical Research Foundation and Princess Alexandra Hospital, University of Queensland, Brisbane, Queensland, Australia.
  • Oncology Center Sf Nectarie Ltd, Craiova, Romania.

ORCID-Profile: Jeffrey S Weber, Dirk Schadendorf, James Larkin, Michael Schenker, Jacopo Pigozzo, Helen Gogas, Paolo A Ascierto, Shahneen Sandhu, Ralf Gutzmer, Jessica C Hassel, Caroline Robert, Marcus O Butler, Eva Muñoz-Couselo, Michael P Brown, Piotr Rutkowski, Andrew Haydon, Jean-Jacques Grob, Luis de la Cruz-Merino, Andre van der Westhuizen, Alexander M Menzies, Daniel J Tenney, Georgina V Long

Förderung

  • NCI NIH HHS

Zitieren

APA

Weber, J. S., Schadendorf, D., Del Vecchio, M., Larkin, J., Atkinson, V., Schenker, M., Pigozzo, J., Gogas, H., Dalle, S., Meyer, N., Ascierto, P. A., Sandhu, S., Eigentler, T., Gutzmer, R., Hassel, J. C., Robert, C., Carlino, M. S., Di Giacomo, A. M., Butler, M. O., …, & Long, G. V. (2023). Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915). Journal of Clinical Oncology, 41(3), 517-527. https://doi.org/10.1200/jco.22.00533

Vancouver

Weber JS, Schadendorf D, Del Vecchio M, Larkin J, Atkinson V, Schenker M, et al. Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915). Journal of Clinical Oncology. 2023;41(3):517-527. doi:10.1200/jco.22.00533

BibTeX
@article{Weber2023,
  author = {Weber, Jeffrey S and Schadendorf, Dirk and Del Vecchio, Michele and Larkin, James and Atkinson, Victoria and Schenker, Michael and Pigozzo, Jacopo and Gogas, Helen and Dalle, Stéphane and Meyer, Nicolas and Ascierto, Paolo A and Sandhu, Shahneen and Eigentler, Thomas and Gutzmer, Ralf and Hassel, Jessica C and Robert, Caroline and Carlino, Matteo S and Di Giacomo, Anna Maria and Butler, Marcus O and Muñoz-Couselo, Eva and Brown, Michael P and Rutkowski, Piotr and Haydon, Andrew and Grob, Jean-Jacques and Schachter, Jacob and Queirolo, Paola and de la Cruz-Merino, Luis and van der Westhuizen, Andre and Menzies, Alexander M and Re, Sandra and Bas, Tuba and de Pril, Veerle and Braverman, Julia and Tenney, Daniel J and Tang, Hao and Long, Georgina V},
  title = {Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  volume = {41},
  number = {3},
  pages = {517--527},
  doi = {10.1200/jco.22.00533}
}
Kostenlos starten →